KEROS THERAPEUTICS INC

KROSNASDAQ

🏆 #2998 by market capEarnings Nov 4US Equity

$10.72▲ $0.08 (+0.75%)

Live

1h▲ 0.8%

24h▲ 0.8%

7d▲ 7.4%

14d▲ 8.0%

30d▼ 3.6%

1y▼ 21.9%

🏦Market Cap

$343M

Small Cap

📈Revenue Growth (YoY)

+6775.0%

High Growth

📊Gross Margin

94.7%

High

💵FCF Margin

-322.9%

Thin

⚖️P/S Ratio

22.7x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $10.55 – $10.87
52-Week Range: $9.69 – $22.55
Volume: $2.12B
Avg Volume: $1.92B
Shares Outstanding: 32.0M
Next Earnings: Oct 20, 2026

Fundamentals Snapshot

Annual Revenue: $244M
Last Q Revenue: $64M
P/E Ratio: -2.9
P/S Ratio: 22.7x
EPS (TTM): $-4.20
Dividend Yield: 0.00%

Why Investors Own KROS

✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
✓Healthy economics — 46% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$244M▲ +26.3% YoY

Gross Margin (TTM)

46.3%▲ +2.3% YoY

Operating Income (TTM)

$89M▲ +26.3% YoY

Free Cash Flow (TTM)

$26M▲ +26.3% YoY

About KEROS THERAPEUTICS INC

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

🦦